Loading...
XASE
CATX
Market cap244mUSD
Jul 10, Last price  
3.02USD
1D
-6.49%
1Q
-29.08%
Jan 2017
-45.34%
IPO
-93.78%
Name

IsoRay Inc

Chart & Performance

D1W1MN
XASE:CATX chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
6.10%
Rev. gr., 5y
-38.51%
Revenues
0k
-100.00%
5,738,0337,158,6905,417,8155,286,0845,238,9735,071,0884,525,2334,219,1584,606,5394,769,2764,761,0005,923,0007,314,0009,680,00010,053,00010,795,0007,104,0001,434,0001,454,0000
Net income
-103m
L+30.07%
-9,605,155-8,557,507-6,160,841-4,033,856-2,842,213-3,488,905-3,856,596-5,959,122-3,681,051-4,710,808-6,162,000-6,700,000-4,850,000-3,269,000-3,188,000-7,153,000-14,670,000-46,508,000-79,279,000-103,121,000
CFO
-82m
L+350.88%
-7,201,710-7,725,298-3,948,936-2,686,403-2,418,910-2,447,775-3,056,267-3,228,221-3,521,858-3,884,000-5,712,000-5,712,000-5,049,000-3,641,000-2,837,000-7,710,000-12,172,000-36,913,000-18,294,000-82,484,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
IPO date
May 31, 2002
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT